Report of endometrial cancer in Australian BRCA1 and BRCA2 mutation-positive families

Twin Research and Human Genetics

Volumn 14, Issue 2, 2011, Pages 111-118

  Duffy, David L ^a   Antill, Yoland C ^b   Stewart, Colin J ^c   Young, Joanne P ^a   Spurdle, Amanda B ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

BRCA1; BRCA2; Endometrial cancer; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS; TAMOXIFEN;

EID: 79953094132     PISSN: 18324274     EISSN: None     Source Type: Journal    
DOI: 10.1375/twin.14.2.111     Document Type: Article

References (34)

1. Arenas, M., Rovirosa, A., Hernandez, V., Ordi, J., Jorcano, S., Mellado, B., & Biete, A. (2006). Uterine sarcomas in breast cancer patients treated with tamoxifen. International Journal of Gynecological Cancer, 16, 861-865.
2. Barak, F., Milgrom, R., Laitman, Y., Gemer, O., Rabinovich, A., Piura, B., Anteby, E., Baruch, G. B., Korach, J., & Friedman, E. (2010). The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. Gynecologic Oncology, 119, 511-515.
3. Beiner, M. E., Finch, A., Rosen, B., Lubinski, J., Moller, P., Ghadirian, P., Lynch, H. T., Friedman, E., Sun, P., & Narod, S. A. (2007). The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic Oncology, 104, 7-10. (Pubitemid 46054134)
4. Bergman, L., Beelen, M. L., Gallee, M. P., Hollema, H., Benraadt, J., & van Leeuwen, F. E. (2000). Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet, 356, 881-887.
5. Biron-Shental, T., Drucker, L., Altaras, M., Bernheim, J., & Fishman, A. (2006). High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. European Journal of Surgical Oncology, 32, 1097-1100. (Pubitemid 44774386)
6. Breast Cancer Linkage Consortium. (1999). Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. Journal of the National Cancer Institute, 91, 1310-1316.
7. Chenevix-Trench, G., Healey, S., Lakhani, S., Waring, P., Cummings, M., Brinkworth, R., Deffenbaugh, A. M., Burbidge, L. A., Pruss, D., Judkins, T., Scholl, T., Bekessy, A., Marsh, A., Lovelock, P., Wong, M., Tesoriero, A., Renard, H., Southey, M., Hopper, J. L., Yannoukakos, K., Brown, M., Easton, D., Tavtigian, S. V., Goldgar, D., & Spurdle, A. B. (2006). Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Research, 66, 2019-2027.
8. Ciernikova, S., Tomka, M., Kovac, M., Stevurkova, V., & Zajac, V. (2006). Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma, 53, 97-102.
9. Curtis, R. E., Freedman, D. M., Sherman, M. E., & Fraumeni, J. F., Jr. (2004). Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. Journal of the National Cancer Institute, 96, 70-74. (Pubitemid 38180962)
10. Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet, 361, 296-300.
11. Early Breast Cancer Trialists', Collaborative Group (1998). Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet, 351, 1451-1467.
12. Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., Neuhausen, S. L., Ford, D., Wooster, R., Cannon-Albright, L. A., Stratton, M. R., & Goldgar, D. E. (1997). Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. American Journal of Human Genetics, 61, 120-128. (Pubitemid 27323331)
13. Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., & Cronin, W. M. (1994). Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [see comments]. Journal of the National Cancer Institute, 86, 527-537. (Pubitemid 24111008)
14. Goshen, R., Chu, W., Elit, L., Pal, T., Hakimi, J., Ackerman, I., Fyles, A., Mitchell, M., & Narod, S. A. (2000). Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecologic Oncology, 79, 477-481.
15. Hornreich, G., Beller, U., Lavie, O., Renbaum, P., Cohen, Y., & Levy-Lahad, E. (1999). Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecologic Oncology, 75, 300-304. (Pubitemid 29523039)
16. Kloos, I., Delaloge, S., Pautier, P., Di Palma, M., Goupil, A., Duvillard, P., Cailleux, P. E., & Lhomme, C. (2002). Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature. International Journal of Gynecology and Cancer, 12, 496-500.
17. Lavie, O., Ben-Arie, A., Pilip, A., Rennert, G., Cohen, Y., Feiner, B., & Auslnader, R. (2005). BRCA2 germline mutation in a woman with uterine serous papillary carcinoma - Case report. Gynecologic Oncology, 99, 486-488. (Pubitemid 41502865)
18. Lavie, O., Hornreich, G., Ben Arie, A., Renbaum, P., Levy-Lahad, E., & Beller, U. (2000). BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstetrics and Gynecology, 96, 28-32. (Pubitemid 30336275)
19. Lavie, O., Hornreich, G., Ben Arie, A., Rennert, G., Cohen, Y., Keidar, R., Sagi, S., Levy-Lahad, E., Auslander, R., & Beller, U. (2004). BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecologic Oncology, 92, 521-524. (Pubitemid 38183139)
20. Levine, D. A., Lin, O., Barakat, R. R., Robson, M. E., McDermott, D., Cohen, L., Satagopan, J., Offit, K., & Boyd, J. (2001). Risk of endometrial carcinoma associated with BRCA mutation. Gynecologic Oncology, 80, 395-398. (Pubitemid 32207542)
21. Magriples, U., Naftolin, F., Schwartz, P. E., & Carcangiu, M. L. (1993). High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. Journal of Clinical Oncology, 11, 485-490. (Pubitemid 23071046)
22. Mann, G. J., Thorne, H., Balleine, R. L., Butow, P. N., Clarke, C. L., Edkins, E., Evans, G. M., Fereday, S., Haan, E., Gattas, M., Giles, G. G., Goldblatt, J., Hopper, J. L., Kirk, J., Leary, J. A., Lindeman, G., Niedermayr, E., Phillips, K. A., Picken, S., Pupo, G. M., Saunders, C., Scott, C. L., Spurdle, A. B., Suthers, G., Tucker, K., & Chenevix-Trench, G. (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8, R12.
23. Mignotte, H., Lasset, C., Bonadona, V., Lesur, A., Luporsi, E., Rodier, J. F., Cutuli, B., Lasry, S., Mauriac, L., Granon, C., Kerr, C., Giard, S., Hill, C., de Lafontan, B., de Gislain, C., D'Anjou, J., Fondrinier, E., Lefeuvre, C., Parache, R. M., & Chauvin, F. (1998). Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). International Journal of Cancer, 76, 325-330. (Pubitemid 28282929)
24. Moinfar, F., Azodi, M., & Tavassoli, F. A. (2007). Uterine sarcomas. Pathology, 39, 55-71.
25. Moslehi, R., Chu, W., Karlan, B., Fishman, D., Risch, H., Fields, A., Smotkin, D., Ben-David, Y., Rosenblatt, J., Russo, D., Schwartz, P., Tung, N., Warner, E., Rosen, B., Friedman, J., Brunet, J. S., & Narod, S. A. (2000). BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. American Journal of Human Genetics, 66, 1259-1272. (Pubitemid 30468783)
26. Osborne, C. K. (1998). Steroid hormone receptors in breast cancer management. Breast Cancer Research and Treatment, 51, 227-238.
27. Parmigiani, G., Chen, S., Wang, W., Katki, H., Blackford, A., Aguilar, O., Chen, S., Gudbjartsson, D.F., Zhou, K., & Iverson, E.S. (2008). BayesMendel: Determining carrier probabilities for cancer susceptibility genes. (Version 2.0-1).
28. R Core Development Team. (2008). R: A language and environment for statistical computing. Retrieved from http://www.R-project.org
29. Saadat, M., Truong, P. T., Kader, H. A., Speers, C. H., Berthelet, E., McMurtrie, E., & Olivotto, I. A. (2007). Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen. Cancer, 110, 31-37.
30. Therneau, T., & Lumley, T. (2008). Survival: Survival analysis, including penalised likelihood. R package version 2.34-1.
31. Thompson, D., & Easton, D. F. (2002). Cancer incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute, 94, 1358-1365. (Pubitemid 35154140)
32. Vicus, D., Rosen, B., Lubinski, J., Domchek, S., Kauff, N. D., Lynch, H. T., Isaacs, C., Tung, N., Sun, P., & Narod, S. A. (2009). Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecologic Oncology, 115, 135-137.
33. Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Jr., Wade, J. L., 3rd, Robidoux, A., Margolese, R. G., James, J., Lippman, S. M., Runowicz, C. D., Ganz, P. A., Reis, S. E., McCaskill-Stevens, W., Ford, L. G., Jordan, V. C., & Wolmark, N. (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 295, 2727-2741.
34. Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., 3rd, Robidoux, A., Margolese, R. G., James, J., Runowicz, C. D., Ganz, P. A., Reis, S. E., McCaskill-Stevens, W., Ford, L. G., Jordan, V. C., & Wolmark, N. (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prevention Research, 3, 696-706.